Reset Map12 Results
760 Pennsylvania Drive Exton, PA, 19341 United StatesAt Frontage, our business is built on collaboration with a broad spectrum of clients across the pharmaceutical and biopharmaceutical industry—from top global pharma companies to emerging start-ups. We support innovator, generic, and consumer health organizations with IND, NDA, ANDA, and 505(b)(2) submissions, delivering flexible, customized solutions to meet each client’s unique needs. • Laboratory Services: DMPK and CMC services delivered by more than 400 scientists across three facilities in the US and China. Our senior scientists average 10–15 years of experience in complex drug development, many with backgrounds in leading pharmaceutical companies. • Global Bioanalysis and Central Laboratories: A rapidly expanding platform with operations in the US, China, and Europe (Milan), supporting Phase I–IV clinical trials. Services include large molecule bioanalysis (PK/ADA/NAb), safety and specialty testing, advanced biomarker solutions (soluble, tissue, flow cytometry), and genomics, all under a harmonized quality system (CLIA, CAP, ISO, ICH GCP). With a focus on protocol agility, risk-based compliance, and global logistics, Frontage offers both scientific expertise and operational flexibility, enabling sponsors to accelerate development while ensuring data quality and regulatory confidence. • Clinical Services: Phase I–IIa and biometrics capabilities, including a 160-bed clinical unit in Secaucus, NJ, and 18 clinical sites with over 300 beds in China. Our biometrics services support programs from early to late stage. Our commitment to scientific rigor and regulatory compliance ensures the highest quality outcomes. Over the years, we have successfully advanced hundreds of molecules from early development through commercial launch in global markets. With an integrated portfolio of laboratory and clinical services, Frontage provides comprehensive support across the entire product development pipeline.
700 Pennsylvania Drive United States Exton, PA, 19341 United StatesAt Frontage, our business is built on collaboration with a broad spectrum of clients across the pharmaceutical and biopharmaceutical industry—from top global pharma companies to emerging start-ups. We support innovator, generic, and consumer health organizations with IND, NDA, ANDA, and 505(b)(2) submissions, delivering flexible, customized solutions to meet each client’s unique needs. • Laboratory Services: DMPK and CMC services delivered by more than 400 scientists across three facilities in the US and China. Our senior scientists average 10–15 years of experience in complex drug development, many with backgrounds in leading pharmaceutical companies. • Global Bioanalysis and Central Laboratories: A rapidly expanding platform with operations in the US, China, and Europe (Milan), supporting Phase I–IV clinical trials. Services include large molecule bioanalysis (PK/ADA/NAb), safety and specialty testing, advanced biomarker solutions (soluble, tissue, flow cytometry), and genomics, all under a harmonized quality system (CLIA, CAP, ISO, ICH GCP). With a focus on protocol agility, risk-based compliance, and global logistics, Frontage offers both scientific expertise and operational flexibility, enabling sponsors to accelerate development while ensuring data quality and regulatory confidence. • Clinical Services: Phase I–IIa and biometrics capabilities, including a 160-bed clinical unit in Secaucus, NJ, and 18 clinical sites with over 300 beds in China. Our biometrics services support programs from early to late stage. Our commitment to scientific rigor and regulatory compliance ensures the highest quality outcomes. Over the years, we have successfully advanced hundreds of molecules from early development through commercial launch in global markets. With an integrated portfolio of laboratory and clinical services, Frontage provides comprehensive support across the entire product development pipeline.
240 Sierra Dr Exton, PA, 19341 United StatesAt Frontage, our business is built on collaboration with a broad spectrum of clients across the pharmaceutical and biopharmaceutical industry—from top global pharma companies to emerging start-ups. We support innovator, generic, and consumer health organizations with IND, NDA, ANDA, and 505(b)(2) submissions, delivering flexible, customized solutions to meet each client’s unique needs. • Laboratory Services: DMPK and CMC services delivered by more than 400 scientists across three facilities in the US and China. Our senior scientists average 10–15 years of experience in complex drug development, many with backgrounds in leading pharmaceutical companies. • Global Bioanalysis and Central Laboratories: A rapidly expanding platform with operations in the US, China, and Europe (Milan), supporting Phase I–IV clinical trials. Services include large molecule bioanalysis (PK/ADA/NAb), safety and specialty testing, advanced biomarker solutions (soluble, tissue, flow cytometry), and genomics, all under a harmonized quality system (CLIA, CAP, ISO, ICH GCP). With a focus on protocol agility, risk-based compliance, and global logistics, Frontage offers both scientific expertise and operational flexibility, enabling sponsors to accelerate development while ensuring data quality and regulatory confidence. • Clinical Services: Phase I–IIa and biometrics capabilities, including a 160-bed clinical unit in Secaucus, NJ, and 18 clinical sites with over 300 beds in China. Our biometrics services support programs from early to late stage. Our commitment to scientific rigor and regulatory compliance ensures the highest quality outcomes. Over the years, we have successfully advanced hundreds of molecules from early development through commercial launch in global markets. With an integrated portfolio of laboratory and clinical services, Frontage provides comprehensive support across the entire product development pipeline.
Lane 67 Libing Road Building 13 Shanghai, Shanghai, 201203 ChinaAt Frontage, our business is built on collaboration with a broad spectrum of clients across the pharmaceutical and biopharmaceutical industry—from top global pharma companies to emerging start-ups. We support innovator, generic, and consumer health organizations with IND, NDA, ANDA, and 505(b)(2) submissions, delivering flexible, customized solutions to meet each client’s unique needs. • Laboratory Services: DMPK and CMC services delivered by more than 400 scientists across three facilities in the US and China. Our senior scientists average 10–15 years of experience in complex drug development, many with backgrounds in leading pharmaceutical companies. • Global Bioanalysis and Central Laboratories: A rapidly expanding platform with operations in the US, China, and Europe (Milan), supporting Phase I–IV clinical trials. Services include large molecule bioanalysis (PK/ADA/NAb), safety and specialty testing, advanced biomarker solutions (soluble, tissue, flow cytometry), and genomics, all under a harmonized quality system (CLIA, CAP, ISO, ICH GCP). With a focus on protocol agility, risk-based compliance, and global logistics, Frontage offers both scientific expertise and operational flexibility, enabling sponsors to accelerate development while ensuring data quality and regulatory confidence. • Clinical Services: Phase I–IIa and biometrics capabilities, including a 160-bed clinical unit in Secaucus, NJ, and 18 clinical sites with over 300 beds in China. Our biometrics services support programs from early to late stage. Our commitment to scientific rigor and regulatory compliance ensures the highest quality outcomes. Over the years, we have successfully advanced hundreds of molecules from early development through commercial launch in global markets. With an integrated portfolio of laboratory and clinical services, Frontage provides comprehensive support across the entire product development pipeline.
760 Pennsylvania Drive Frontage Global Central Laboratories Exton, PA, 19341 United StatesAt Frontage, our business is built on collaboration with a broad spectrum of clients across the pharmaceutical and biopharmaceutical industry—from top global pharma companies to emerging start-ups. We support innovator, generic, and consumer health organizations with IND, NDA, ANDA, and 505(b)(2) submissions, delivering flexible, customized solutions to meet each client’s unique needs. • Laboratory Services: DMPK and CMC services delivered by more than 400 scientists across three facilities in the US and China. Our senior scientists average 10–15 years of experience in complex drug development, many with backgrounds in leading pharmaceutical companies. • Global Bioanalysis and Central Laboratories: A rapidly expanding platform with operations in the US, China, and Europe (Milan), supporting Phase I–IV clinical trials. Services include large molecule bioanalysis (PK/ADA/NAb), safety and specialty testing, advanced biomarker solutions (soluble, tissue, flow cytometry), and genomics, all under a harmonized quality system (CLIA, CAP, ISO, ICH GCP). With a focus on protocol agility, risk-based compliance, and global logistics, Frontage offers both scientific expertise and operational flexibility, enabling sponsors to accelerate development while ensuring data quality and regulatory confidence. • Clinical Services: Phase I–IIa and biometrics capabilities, including a 160-bed clinical unit in Secaucus, NJ, and 18 clinical sites with over 300 beds in China. Our biometrics services support programs from early to late stage. Our commitment to scientific rigor and regulatory compliance ensures the highest quality outcomes. Over the years, we have successfully advanced hundreds of molecules from early development through commercial launch in global markets. With an integrated portfolio of laboratory and clinical services, Frontage provides comprehensive support across the entire product development pipeline.
101 – 8898 Heather Street Vancouver, British Columbia, V6P 3S8 CanadaAt Frontage, our business is built on collaboration with a broad spectrum of clients across the pharmaceutical and biopharmaceutical industry—from top global pharma companies to emerging start-ups. We support innovator, generic, and consumer health organizations with IND, NDA, ANDA, and 505(b)(2) submissions, delivering flexible, customized solutions to meet each client’s unique needs. • Laboratory Services: DMPK and CMC services delivered by more than 400 scientists across three facilities in the US and China. Our senior scientists average 10–15 years of experience in complex drug development, many with backgrounds in leading pharmaceutical companies. • Global Bioanalysis and Central Laboratories: A rapidly expanding platform with operations in the US, China, and Europe (Milan), supporting Phase I–IV clinical trials. Services include large molecule bioanalysis (PK/ADA/NAb), safety and specialty testing, advanced biomarker solutions (soluble, tissue, flow cytometry), and genomics, all under a harmonized quality system (CLIA, CAP, ISO, ICH GCP). With a focus on protocol agility, risk-based compliance, and global logistics, Frontage offers both scientific expertise and operational flexibility, enabling sponsors to accelerate development while ensuring data quality and regulatory confidence. • Clinical Services: Phase I–IIa and biometrics capabilities, including a 160-bed clinical unit in Secaucus, NJ, and 18 clinical sites with over 300 beds in China. Our biometrics services support programs from early to late stage. Our commitment to scientific rigor and regulatory compliance ensures the highest quality outcomes. Over the years, we have successfully advanced hundreds of molecules from early development through commercial launch in global markets. With an integrated portfolio of laboratory and clinical services, Frontage provides comprehensive support across the entire product development pipeline.
3801 Bay Center Pl Hayward, CA, 94545-3619 United StatesAt Frontage, our business is built on collaboration with a broad spectrum of clients across the pharmaceutical and biopharmaceutical industry—from top global pharma companies to emerging start-ups. We support innovator, generic, and consumer health organizations with IND, NDA, ANDA, and 505(b)(2) submissions, delivering flexible, customized solutions to meet each client’s unique needs. • Laboratory Services: DMPK and CMC services delivered by more than 400 scientists across three facilities in the US and China. Our senior scientists average 10–15 years of experience in complex drug development, many with backgrounds in leading pharmaceutical companies. • Global Bioanalysis and Central Laboratories: A rapidly expanding platform with operations in the US, China, and Europe (Milan), supporting Phase I–IV clinical trials. Services include large molecule bioanalysis (PK/ADA/NAb), safety and specialty testing, advanced biomarker solutions (soluble, tissue, flow cytometry), and genomics, all under a harmonized quality system (CLIA, CAP, ISO, ICH GCP). With a focus on protocol agility, risk-based compliance, and global logistics, Frontage offers both scientific expertise and operational flexibility, enabling sponsors to accelerate development while ensuring data quality and regulatory confidence. • Clinical Services: Phase I–IIa and biometrics capabilities, including a 160-bed clinical unit in Secaucus, NJ, and 18 clinical sites with over 300 beds in China. Our biometrics services support programs from early to late stage. Our commitment to scientific rigor and regulatory compliance ensures the highest quality outcomes. Over the years, we have successfully advanced hundreds of molecules from early development through commercial launch in global markets. With an integrated portfolio of laboratory and clinical services, Frontage provides comprehensive support across the entire product development pipeline.
4045 S Morgan St Chicago, IL, 60609 2514 United StatesAt Frontage, our business is built on collaboration with a broad spectrum of clients across the pharmaceutical and biopharmaceutical industry—from top global pharma companies to emerging start-ups. We support innovator, generic, and consumer health organizations with IND, NDA, ANDA, and 505(b)(2) submissions, delivering flexible, customized solutions to meet each client’s unique needs. • Laboratory Services: DMPK and CMC services delivered by more than 400 scientists across three facilities in the US and China. Our senior scientists average 10–15 years of experience in complex drug development, many with backgrounds in leading pharmaceutical companies. • Global Bioanalysis and Central Laboratories: A rapidly expanding platform with operations in the US, China, and Europe (Milan), supporting Phase I–IV clinical trials. Services include large molecule bioanalysis (PK/ADA/NAb), safety and specialty testing, advanced biomarker solutions (soluble, tissue, flow cytometry), and genomics, all under a harmonized quality system (CLIA, CAP, ISO, ICH GCP). With a focus on protocol agility, risk-based compliance, and global logistics, Frontage offers both scientific expertise and operational flexibility, enabling sponsors to accelerate development while ensuring data quality and regulatory confidence. • Clinical Services: Phase I–IIa and biometrics capabilities, including a 160-bed clinical unit in Secaucus, NJ, and 18 clinical sites with over 300 beds in China. Our biometrics services support programs from early to late stage. Our commitment to scientific rigor and regulatory compliance ensures the highest quality outcomes. Over the years, we have successfully advanced hundreds of molecules from early development through commercial launch in global markets. With an integrated portfolio of laboratory and clinical services, Frontage provides comprehensive support across the entire product development pipeline.
Shanghai, ChinaAt Frontage, our business is built on collaboration with a broad spectrum of clients across the pharmaceutical and biopharmaceutical industry—from top global pharma companies to emerging start-ups. We support innovator, generic, and consumer health organizations with IND, NDA, ANDA, and 505(b)(2) submissions, delivering flexible, customized solutions to meet each client’s unique needs. • Laboratory Services: DMPK and CMC services delivered by more than 400 scientists across three facilities in the US and China. Our senior scientists average 10–15 years of experience in complex drug development, many with backgrounds in leading pharmaceutical companies. • Global Bioanalysis and Central Laboratories: A rapidly expanding platform with operations in the US, China, and Europe (Milan), supporting Phase I–IV clinical trials. Services include large molecule bioanalysis (PK/ADA/NAb), safety and specialty testing, advanced biomarker solutions (soluble, tissue, flow cytometry), and genomics, all under a harmonized quality system (CLIA, CAP, ISO, ICH GCP). With a focus on protocol agility, risk-based compliance, and global logistics, Frontage offers both scientific expertise and operational flexibility, enabling sponsors to accelerate development while ensuring data quality and regulatory confidence. • Clinical Services: Phase I–IIa and biometrics capabilities, including a 160-bed clinical unit in Secaucus, NJ, and 18 clinical sites with over 300 beds in China. Our biometrics services support programs from early to late stage. Our commitment to scientific rigor and regulatory compliance ensures the highest quality outcomes. Over the years, we have successfully advanced hundreds of molecules from early development through commercial launch in global markets. With an integrated portfolio of laboratory and clinical services, Frontage provides comprehensive support across the entire product development pipeline.
32 Via Tiziano Milano, Lombardia, 20145 ItalyAt Frontage, our business is built on collaboration with a broad spectrum of clients across the pharmaceutical and biopharmaceutical industry—from top global pharma companies to emerging start-ups. We support innovator, generic, and consumer health organizations with IND, NDA, ANDA, and 505(b)(2) submissions, delivering flexible, customized solutions to meet each client’s unique needs. • Laboratory Services: DMPK and CMC services delivered by more than 400 scientists across three facilities in the US and China. Our senior scientists average 10–15 years of experience in complex drug development, many with backgrounds in leading pharmaceutical companies. • Global Bioanalysis and Central Laboratories: A rapidly expanding platform with operations in the US, China, and Europe (Milan), supporting Phase I–IV clinical trials. Services include large molecule bioanalysis (PK/ADA/NAb), safety and specialty testing, advanced biomarker solutions (soluble, tissue, flow cytometry), and genomics, all under a harmonized quality system (CLIA, CAP, ISO, ICH GCP). With a focus on protocol agility, risk-based compliance, and global logistics, Frontage offers both scientific expertise and operational flexibility, enabling sponsors to accelerate development while ensuring data quality and regulatory confidence. • Clinical Services: Phase I–IIa and biometrics capabilities, including a 160-bed clinical unit in Secaucus, NJ, and 18 clinical sites with over 300 beds in China. Our biometrics services support programs from early to late stage. Our commitment to scientific rigor and regulatory compliance ensures the highest quality outcomes. Over the years, we have successfully advanced hundreds of molecules from early development through commercial launch in global markets. With an integrated portfolio of laboratory and clinical services, Frontage provides comprehensive support across the entire product development pipeline.
700 Pennsylvania Drive Exton, PA, 19341 United StatesAt Frontage, our business is built on collaboration with a broad spectrum of clients across the pharmaceutical and biopharmaceutical industry—from top global pharma companies to emerging start-ups. We support innovator, generic, and consumer health organizations with IND, NDA, ANDA, and 505(b)(2) submissions, delivering flexible, customized solutions to meet each client’s unique needs. • Laboratory Services: DMPK and CMC services delivered by more than 400 scientists across three facilities in the US and China. Our senior scientists average 10–15 years of experience in complex drug development, many with backgrounds in leading pharmaceutical companies. • Global Bioanalysis and Central Laboratories: A rapidly expanding platform with operations in the US, China, and Europe (Milan), supporting Phase I–IV clinical trials. Services include large molecule bioanalysis (PK/ADA/NAb), safety and specialty testing, advanced biomarker solutions (soluble, tissue, flow cytometry), and genomics, all under a harmonized quality system (CLIA, CAP, ISO, ICH GCP). With a focus on protocol agility, risk-based compliance, and global logistics, Frontage offers both scientific expertise and operational flexibility, enabling sponsors to accelerate development while ensuring data quality and regulatory confidence. • Clinical Services: Phase I–IIa and biometrics capabilities, including a 160-bed clinical unit in Secaucus, NJ, and 18 clinical sites with over 300 beds in China. Our biometrics services support programs from early to late stage. Our commitment to scientific rigor and regulatory compliance ensures the highest quality outcomes. Over the years, we have successfully advanced hundreds of molecules from early development through commercial launch in global markets. With an integrated portfolio of laboratory and clinical services, Frontage provides comprehensive support across the entire product development pipeline.
200 Meadowlands Parkway Secaucus, NJ, 07094 United StatesAt Frontage, our business is built on collaboration with a broad spectrum of clients across the pharmaceutical and biopharmaceutical industry—from top global pharma companies to emerging start-ups. We support innovator, generic, and consumer health organizations with IND, NDA, ANDA, and 505(b)(2) submissions, delivering flexible, customized solutions to meet each client’s unique needs. • Laboratory Services: DMPK and CMC services delivered by more than 400 scientists across three facilities in the US and China. Our senior scientists average 10–15 years of experience in complex drug development, many with backgrounds in leading pharmaceutical companies. • Global Bioanalysis and Central Laboratories: A rapidly expanding platform with operations in the US, China, and Europe (Milan), supporting Phase I–IV clinical trials. Services include large molecule bioanalysis (PK/ADA/NAb), safety and specialty testing, advanced biomarker solutions (soluble, tissue, flow cytometry), and genomics, all under a harmonized quality system (CLIA, CAP, ISO, ICH GCP). With a focus on protocol agility, risk-based compliance, and global logistics, Frontage offers both scientific expertise and operational flexibility, enabling sponsors to accelerate development while ensuring data quality and regulatory confidence. • Clinical Services: Phase I–IIa and biometrics capabilities, including a 160-bed clinical unit in Secaucus, NJ, and 18 clinical sites with over 300 beds in China. Our biometrics services support programs from early to late stage. Our commitment to scientific rigor and regulatory compliance ensures the highest quality outcomes. Over the years, we have successfully advanced hundreds of molecules from early development through commercial launch in global markets. With an integrated portfolio of laboratory and clinical services, Frontage provides comprehensive support across the entire product development pipeline.
Site Information
The Contract Research Map is owned and maintained by Scientist.com. It was created to help researchers in the life sciences identify and connect with contract research organizations (CROs) based on geography. Updated nightly, this map features all of the available CROs within our network, so you can order services with a few clicks. Click on a specific country, scroll on the map itself or type into the search bar at the top—there are many ways to find the location and suppliers that you’re looking for. From Argentina to New Zealand, use this map to connect with a CRO near you.
We believe that every researcher across the world should be able to connect with the thousands of global CROs that exist and have the opportunity to work together. Like many industries,the life science supply chain has been disrupted over the last year. But there are many other circumstances such as international customs regulations or sensitive shipping times that create limitations around which countries are feasible to partner with. Sometimes, finding a CRO based in a country that best suits your research needs is imperative. We hope this contract research map allows you to find the right partner in the right place at the right time.
Have questions or feedback? We’d love to help. You can find our FAQs and contact information on the Learn more page.
Interested in connecting with one or more of the contract research organizations listed on this map? By clicking on the company’s name, you will be directed to their supplier profile on the Scientist.com marketplace. Once you set up a marketplace account you can start the ordering process immediately.
What is Scientist.com?
Scientist.com is the world's largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies.
How can I use Scientist.com?
Scientist.com has built private, enterprise marketplaces from 24 of the 30 largest pharmaceutical companies, 80+ biotech companies, the US National Institutes of Health (NIH) and numerous other pharma and biotech companies. If you are employed by one of these organizations, you can log in to get started today. If you are unsure about how to get started, you can email our team at support@scientist.com or go to our website www.scientist.comto speak to someone via our live chat.
Why should I place my order through Scientist.com?
Scientist.com is a highly efficient enterprise-wide outsourcing marketplace that makes it possible for research organizations to save time and money, access innovation and ensure compliance. It utilizes a universal legal agreement and AI technologies to enable research like never before. See how comparing proposals and getting 1-on-1 support from our Research Concierge® team will enable you to place more research today.
How do I get my organization listed on the map?
If your CRO isn’t showing up on the map, then please be sure your company profile is up to date in Scientist.com’s Backoffice. After logging in, click the Your Company button in the navigation at the top, and then select the Locations tab.
Information about my organization is incorrect, how do I fix it?
Head over to backoffice.scientist.com to update your supplier profile and information. It may take up to two business days for the updates to be reflected on the map.